Emily Roberts
Lawyers

Filters
Turning Point Therapeutics $460 million stock offering
Davis Polk advised the joint book-running managers in connection with a $460 million SEC-registered common stock offering by Turning Point Therapeutics, Inc. The common stock is listed…
Equinix bond offering, including $1.35 billion in inaugural green bonds
Davis Polk advised Equinix, Inc. on an SEC-registered offering of $1.85 billion aggregate principal amount of senior notes. The offering consisted of $700 million aggregate principal amount…
Palantir Technologies direct listing
The shares are listed on the New York Stock Exchange
CrowdStrike $96 million acquisition of Preempt Security
Davis Polk is advising CrowdStrike Holdings, Inc. in connection with its acquisition of Preempt Security, Inc., a leading provider of Zero Trust and conditional access technology for real…
Uber Technologies $500 million senior notes offering
Davis Polk advised the representative of the initial purchasers in connection with a Rule 144A/Regulation S offering by Uber Technologies, Inc. of $500 million aggregate principal…
Rackspace Technology $600 million cash tender offer
Davis Polk advised the dealer manager in connection with a cash tender offer by Rackspace Technology Global, Inc., an indirect subsidiary of Rackspace Technology, Inc., for up to $600…
Chegg $1 billion convertible senior notes offering
Davis Polk advised the representative of the initial purchasers in connection with a Rule 144A offering by Chegg, Inc. of $1 billion aggregate principal amount of its 0% convertible…
Five Prime Therapeutics $75 million at-the-market offering
Davis Polk advised the sales agent on the SEC-registered at-the-market offering by Five Prime Therapeutics, Inc. of its common stock for up to an aggregate amount of $75 million.
Five…
Atreca $100 million at-the-market offering
Davis Polk advised the sales agent on the SEC-registered at-the-market offering by Atreca, Inc. of its common stock for up to an aggregate amount of $100 million.
Atreca is a…
Turning Point Therapeutics $250 million at-the-market offering
Davis Polk advised the sales agent on the SEC-registered at-the-market offering by Turning Point Therapeutics, Inc. of its common stock for up to an aggregate amount of $250 million…